Press releases

3 November 2014

Verona Pharma announces Venture and Innovation Award from the Cystic Fibrosis Trust

Funds further studies exploring potential for RPL554 as a novel treatment for CF Verona Pharma first drug development company to receive Award 3 November 2014, Cardiff – Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicine…

Read more

29 September 2014

New data supports RPL554 as a potential novel cystic fibrosis therapy

29 September 2014, Cardiff – Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, reports that RPL554, the Company’s lead molecule, currently in phase 2 clinical development for the treat…

Read more

9 September 2014

RPL554 presentations at ERS Congress highlight its valuable potential in combination therapy for COPD and other respiratory diseases

9 Sept 2014, Cardiff – Verona Pharma plc (AIM: VRP), the drug development company focused on first-in- class medicines to treat respiratory diseases, announces that today two posters discussing the potential of RPL554 as a combination therapy with anticholinerg…

Read more

23 June 2014

Verona Pharma reports Phase IIa headline results for VRP700

Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, today announces that the Phase IIa clinical trial, to evaluate the efficacy of a single dose of VRP700 as a novel treatment for chroni…

Read more

21 May 2014

Data highlighting synergistic action of novel dual PDE3/4 inhibitor RPL554 with muscarinic receptor antagonists and beta-adrenoceptor agonists in reversing bronchoconstriction presented at ATS international conference

Verona Pharma plc (AIM: VRP), the drug development company focused on “first-in-class” medicines to treat respiratory diseases, today announces that a poster was presented on Tuesday 20 May as part of the scientific programme at American Thoracic Society (ATS) I…

Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us